Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Net Income (2020 - 2025)

Lyell Immunopharma's Net Income history spans 5 years, with the latest figure at -$34.0 million for Q3 2025.

  • For Q3 2025, Net Income rose 23.69% year-over-year to -$34.0 million; the TTM value through Sep 2025 reached -$327.6 million, down 71.61%, while the annual FY2024 figure was -$334.7 million, 49.71% down from the prior year.
  • Net Income for Q3 2025 was -$34.0 million at Lyell Immunopharma, up from -$43.9 million in the prior quarter.
  • Across five years, Net Income topped out at -$11.3 million in Q4 2022 and bottomed at -$196.2 million in Q4 2024.
  • The 5-year median for Net Income is -$52.4 million (2023), against an average of -$57.0 million.
  • The largest annual shift saw Net Income soared 76.0% in 2022 before it plummeted 362.66% in 2023.
  • A 5-year view of Net Income shows it stood at -$47.2 million in 2021, then skyrocketed by 76.0% to -$11.3 million in 2022, then crashed by 362.66% to -$52.4 million in 2023, then plummeted by 274.31% to -$196.2 million in 2024, then soared by 82.68% to -$34.0 million in 2025.
  • Per Business Quant, the three most recent readings for LYEL's Net Income are -$34.0 million (Q3 2025), -$43.9 million (Q2 2025), and -$53.5 million (Q1 2025).